Results
The ANODE trial reported a statistically significant reduction in infection rates with the co-amoxiclav intervention, this was found to yield an improvement of 0.017 QALYs over the placebo1. The cost to the NHS of the intervention was also lower at £120 over 6 weeks compared to the placebo’s £194. This gives an ICER of -£4403.14/QALY. Sensitivity analysis confirmed that the intervention was dominant.